Docket No.: PHOE-0060 Inventor: Mike A. Clark et al.
Title: Methods For Predicting Sensitivity of Tumors to Arginine Deprivation
Sheet 1 of 4

Figure 1

Figure 1. RT-PCR of samples from human tumor cell lines. Lane 1, molecular weight standards (from top to bottom: 5148 bp, 4973 bp, 4268 bp, 3530 bp, 1352 bp, 1078 bp, 872 bp, 603 bp, 310 bp); lane 2, A764 cells; lane 3, HTB-44 cells: lane 4, CRL 1932 cells; lane 5, CRL 1933 cells; lane 6, HB 8064 cells; lane 7, HB 8065 cells; lane 8, WRL 68 cells; lane 9, HEP3B cells; lane 10, HTB92 cells; lane 11, SKHEP3 cells; lane 12, SKHEP2; lane 13, SKHEP1 cells.

Docket No.: PHOE-0060 Inventor: Mike A. Clark et al.
Title: Methods For Predicting Sensitivity of Tumors to
Arginine Deprivation
Sheet 2 of 4

Figure 2

Figure 2A. Northern blot of RNA from human tumor cell lines probed using human argininosuccinate lyase cDNA. Lane 1, SK-mel 2 melanoma; lane 2, SK-mel 3 melanoma; lane 3, SK-mel 28 melanoma; lane 4, MeWo lymphoma; lane 5, T47-D breast adenocarcinoma; lane 6, A549 lung carcinoma; lane 7, HB 8065 hepatoma; lane 8, HTB 52 hepatoma.

Figure 2B. Northern blot of RNA from human tumor cell lines probed using human argininosuccinate synthetase cDNA. Lane 1, SK-mel 2 melanoma; lane 2, SK-mel 3 melanoma; lane 3, SK-mel 28 melanoma; lane 4, MeWo lymphoma; lane 5, T47-D breast adenocarcinoma; lane 6, A549 lung carcinoma; lane 7, HB 8065 hepatoma; lane 8, HTB 52 hepatoma.

Docket No.: PHOE-0060 Inventor: Mike A. Clark et al.
Title: Methods For Predicting Sensitivity of Tumors to
Arginine Deprivation
Sheet 3 of 4

Figure 3

Effects of ADI on Human Melanoma Cells
Transfected with Argininosuccinate Synthase

Figure 4

Figure 4. Western blot using anti-argininosuccinate antibody. Lane 1, prestained molecular weight markers (top to bottom in KDa: 98, 64, 50, 36, 30, 16, 6); lane 2, purified recombinant argininosuccinate synthetase.